We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Pharmaceutical sales forces have expanded rapidly in recent years, but reductions in the time physicians are willing to spend with sales representatives combined with the increased risk of prosecution and civil litigation stemming from sales and marketing practices are making it difficult for drugmakers to balance rising sales expenses. If sales reps can’t meet with physicians or aren’t effective in promoting products, sales will suffer. If reps adopt tactics that violate false claims or antikickback statutes, legal costs and settlements can take a major bite out of earnings and subject the company to ongoing oversight and reporting requirements. This issue of FDL examines Rx sales training strategies to mitigate legal and regulatory compliance risk while turning challenges into opportunities to effectively communicate product benefits to physicians.